0000899243-16-016850.txt : 20160329 0000899243-16-016850.hdr.sgml : 20160329 20160329190852 ACCESSION NUMBER: 0000899243-16-016850 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160328 FILED AS OF DATE: 20160329 DATE AS OF CHANGE: 20160329 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Seres Therapeutics, Inc. CENTRAL INDEX KEY: 0001609809 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274326290 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 440 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617 945 9626 MAIL ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 440 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Seres Health, Inc. DATE OF NAME CHANGE: 20140603 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Shaff Eric D. CENTRAL INDEX KEY: 0001643734 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37465 FILM NUMBER: 161536686 MAIL ADDRESS: STREET 1: C/O SERES HEALTH, INC. STREET 2: 161 FIRST STREET CITY: CAMBRIDGE STATE: MA ZIP: 02472 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2016-03-28 0 0001609809 Seres Therapeutics, Inc. MCRB 0001643734 Shaff Eric D. C/O SERES THERAPEUTICS, INC. 215 FIRST STREET CAMBRIDGE MA 02142 0 1 0 0 CFO and EVP Common Stock 2016-03-28 4 M 0 5473 7.79 A 5473 D Common Stock 2016-03-28 4 S 0 5473 24.07 D 0 D Stock Option (right to buy) 7.79 2016-03-28 4 M 0 5473 0.00 D 2024-12-08 Common Stock 5473 257219 D The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $24.00 to $24.21. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The option vested as to 25% of the shares subject to the option on November 17, 2015, and has vested or will vest as to an additional 6.25% of the total number of shares subject to the option upon the completion of each three consecutive months of service thereafter. /s/ Eric D. Shaff 2016-03-29